Research
Intensified liver-directed radionuclide therapy shows promise for patients with metastatic neuroendocrine tumors
The Brief
- Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic neuroendocrine tumours.
- The approach still delivers treatment throughout the whole body, according to the source report.
- The report is a Medical Xpress news summary; the source text available is a short excerpt.
Why it matters
It offers a way to concentrate radiation dose on liver-dominant metastatic neuroendocrine tumours while retaining systemic coverage, which may inform future treatment design for this patient group.
Who’s affected
- patients with metastatic neuroendocrine tumours
- oncologists and nuclear medicine specialists
- #neuroendocrine tumours
- #radionuclide therapy
- #PRRT
- #liver metastases
- #oncology
Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic neuroendocrine tumors (NETs) while still effectively delivering treatment throughout the whole body. This…
Timeline
Medical Xpress reported on intensified liver-directed PRRT for metastatic neuroendocrine tumours
Medical Xpress - latest medical and health news stories
Intensified liver-directed radionuclide therapy shows promise for patients with metastatic neuroendocrine tumors